TrialThe Lancet. Haematology2018

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Kieron Dunleavy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.